Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Efmoroctocog Alfa→

Efmoroctocog Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1270012-79-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human coagulation factor VIII Fc-fusion protein (extended half-life)
Mechanism of action
Replaces deficient factor VIII in haemophilia A. Factor VIII binds von Willebrand factor in circulation; activated factor VIII acts as a cofactor for activated factor IX to convert factor X to activated factor X, restoring thrombin generation and clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in congenital haemophilia A (factor VIII deficiency), including routine prophylaxis and bleed control according to product-specific dosing

Sources: EMA Elocta EPAR · EMA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Efmoroctocog Alfa Environmental Risk Assessment (ERA) (the Efmoroctocog Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.